Novo Nordisk ( (NVO) ) has provided an update.
On March 27, 2025, Novo Nordisk A/S held its Annual General Meeting, highlighting significant growth in 2024 driven by innovation and capacity expansion. The meeting approved the 2024 Annual Report, a final dividend of DKK 7.90 per share, and the re-election of key board members, including Helge Lund as chair. Additionally, Deloitte was appointed as the auditor, and the board was authorized to repurchase shares and extend share capital. These decisions reflect Novo Nordisk’s commitment to scaling operations to meet rising demand, benefiting over 45 million people with diabetes and obesity worldwide.
More about Novo Nordisk
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. It focuses on pioneering scientific breakthroughs to defeat serious chronic diseases, particularly diabetes. The company employs about 76,300 people across 80 countries and markets its products in approximately 170 countries. Novo Nordisk’s B shares are listed on Nasdaq Copenhagen and its ADRs on the New York Stock Exchange.
YTD Price Performance: -20.82%
Average Trading Volume: 8,458,439
Technical Sentiment Signal: Buy
Current Market Cap: $305.5B
See more insights into NVO stock on TipRanks’ Stock Analysis page.